Polo-like Kinase 1 Inhibitors and Their Potential Role in Anticancer Therapy, with a Focus on NSCLC

被引：58
|
作者：
Medema, Rene H. [1 ,2 ]
Lin, Chia-Chi [3 ]
Yang, James Chih-Hsin [3 ,4 ,5 ]
机构：
[1] Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Canc Genom Ctr, Utrecht, Netherlands
[3] Natl Taiwan Univ, Dept Oncol, Taipei 10764, Taiwan
[4] Natl Taiwan Univ, Grad Inst Oncol, Taipei 10764, Taiwan
[5] Natl Taiwan Univ, Canc Res Ctr, Taipei 10764, Taiwan
来源：
CLINICAL CANCER RESEARCH | 2011年 / 17卷 / 20期
关键词：
CELL LUNG-CANCER; PHASE-III TRIAL; SMALL INTERFERING RNA; CHEMOTHERAPY REGIMENS; TUMOR-GROWTH; BI; 2536; PLK1; MUTATIONS; DOCETAXEL; CARBOPLATIN;
D O I：
10.1158/1078-0432.CCR-11-0541
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Cytotoxic platinum-doublet chemotherapy that includes antimitotic agents is a current standard of care in advanced non-small cell lung cancer (NSCLC). Microtubule-targeting antimitotics, taxanes, and Vinca alkaloids are effective anticancer therapeutics that affect both dividing and nondividing cells. A new generation of antimitotic agents that target regulatory proteins-mitotic kinases and kinesins-has the potential to overcome the limitations related to the role of tubulin in nondividing cells that are associated with traditional antimitotics. This review concentrates on Polo-like kinase 1, a key regulator of mitosis, outlines a rationale for its development as an anticancer target, and discusses data from preclinical and clinical studies of Plk1 inhibitors with a particular focus on NSCLC. Clin Cancer Res; 17(20); 6459-66. (C) 2011 AACR.
引用
收藏
页码：6459 / 6466
页数：8
相关论文
共 50 条
  • [41] Identification of Novel Polo-like Kinase 1 Inhibitors by a Hybrid Virtual Screening
    Lu, Shuai
    Sun, Shan-Liang
    Liu, Hai-Chun
    Chen, Ya-Dong
    Yuan, Hao-Liang
    Gao, Yi-Ping
    Yang, Pei
    Lu, Tao
    CHEMICAL BIOLOGY & DRUG DESIGN, 2012, 80 (02) : 328 - 339
  • [42] Therapeutic potential of targeting polo-like kinase 4
    Lei, Qian
    Yu, Quanwei
    Yang, Na
    Xiao, Zhaolin
    Song, Chao
    Zhang, Rui
    Yang, Shuxin
    Liu, Zhihao
    Deng, Hui
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 265
  • [43] Current clinical trials with polo-like kinase 1 inhibitors in solid tumors
    Yim, Hyungshin
    ANTI-CANCER DRUGS, 2013, 24 (10) : 999 - 1006
  • [44] Peptide-derived inhibitors targeting polo-like kinase 1 for anti-cancer therapy
    Park, J-E.
    Liu, F.
    Qian, W-J.
    Lim, D.
    Bang, J. K.
    Yaffe, M. B.
    Burke, T. R., Jr.
    Lee, K. S.
    JOURNAL OF PEPTIDE SCIENCE, 2012, 18 : S51 - S51
  • [45] Characterization of small molecular weight inhibitors of polo-like kinase-1
    Plyte, SE
    Belham, C
    Beria, I
    Berthelsen, J
    Brasca, G
    Cappella, P
    Sola, F
    Caruso, M
    ANNALS OF ONCOLOGY, 2006, 17 : 37 - 37
  • [46] Computational Design of Targeted Inhibitors of Polo-Like Kinase 1 (Plk1)
    Jani, Krupa S.
    Dalafave, D. S.
    BIOINFORMATICS AND BIOLOGY INSIGHTS, 2012, 6 : 23 - 31
  • [47] Polo-Like Kinases Inhibitors
    Garuti, L.
    Roberti, M.
    Bottegoni, G.
    CURRENT MEDICINAL CHEMISTRY, 2012, 19 (23) : 3937 - 3948
  • [48] Characterization of small molecular weight inhibitors of Polo-like kinase-1
    Plyte, Simon E.
    Belham, Christopher
    Beria, Italo
    Berthelsen, Jens
    Brasca, Gabriella
    Cappella, Paolo
    Sola, Francesco
    Caruso, Michele
    CANCER RESEARCH, 2006, 66 (08)
  • [49] Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma
    Stehle, Angelika
    Hugle, Manuela
    Fulda, Simone
    CANCER LETTERS, 2015, 365 (01) : 37 - 46
  • [50] Role for polo-like kinase 4 in mediation of cytokinesis
    Press, Michael F.
    Xie, Bin
    Davenport, Simon
    Zhou, Yu
    Guzman, Roberta
    Nolan, Garry P.
    O'Brien, Neil
    Palazzolo, Michael
    Mak, Tak W.
    Brugge, Joan S.
    Slamon, Dennis J.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (23) : 11309 - 11318
12345